Mimetikos Preludium™ Software

Mimetikos Preludium™ Software

A modeling package for estimating regional deposition of inhaled aerosols in the human respiratory tract includes a pharmacokinetic (PK)-module to simulate what happens ’after the particle has landed’ to the patients airways.

Mimetikos Preludium Software

Mimetikos Preludium™ Software

Mimetikos Preludium™ software is a modeling package for estimating regional deposition of inhaled aerosols in the human respiratory tract and its fate through its appearance in the blood stream until eliminated from the body. The modeling package is particularly focused on pharmaceutical aerosols but is equally applicable to environmental aerosols.

Although the software is primarily a research tool, its nearly instant response, graphical abilities and in-depth details makes it superb for educational purposes and ‘what-if’ analyses.

Mimetikos Preludium™ calculates regional deposition of mono- or polydisperse aerosols in the airways of adults and children ranging from ultrafine (<0.01 μm) to coarse (>50 μm) particles. It uses adjustable typical-path literature lung models in which air flow, lung volume and particle transport are modeled in accord with the dynamics of the expanding and contracting lung.

Deposition in lung airways is calculated by user-selectable probability functions taken from the literature for combined deposition by impaction, sedimentation and diffusion. Deposition in mouth or nose are based on a range of empirical/semi-empirical functions.

Mimetikos preludium software
Mimetikos preludium software

Mimetikos Preludium™ – Focus on Pharmaceutical Aerosols

All existing lung deposition models in the literature were developed with tidal breathing of environmental aerosols in focus. Mimetikos Preludium™ software is to our knowledge unique in its focus on pharmaceutical aerosols:

The inhalation-pause-exhalation cycle allows an adjustable flow rate versus time variation.

Aerosol may be inhaled as a bolus anywhere in the inhalation profile.

Regression algorithms included to fit the flow rate cycle and bolus parameters to experimental data.

Regression algorithms included to fit cascade impactor data to a three-parameter particle size distribution model. The most widely used impactors are built-in and the user can also construct his own impactor.

Support for the confined jet algorithm for mouth deposition of dry powder inhaler and nebulizer aerosols.

Compatible with experimentally determined mouth deposition, e.g. cast filtration for pressurized metered dose aerosols.

Mimetikos Preludium™ – PK Model

The PK model simulates the fate of deposited aerosol, aiming to narrow the gap between deposition predictions and clinically observable parameters in order to facilitate product development and clinical study interpretations.

Pulmonary processes are described mechanistically (dissolution, barrier permeation, blood tissue perfusion, mucociliary clearance) whereas other processes are empirical (absorption from gastrointestinal tract, central and peripheral distribution and central clearance). Parameters for lung physiology, compound and formulation properties and summary parameters for compound interaction with tissues are inputs for the mechanistic model parts. Compartmental rate constants are inputs for the empirical model parts. Outputs include the concentration-time curve of all compartments and summary parameters such as AUC, Cmax and BA.

Mimetikos preludium software

Technical Specifications – Mimetikos Preludium™ Software

Mimetikos Preludium™ software is a Windows application written in MS Visual Studio (.NET) and runs on Windows XP or later. It is available for both 32 and 64-bit OS.

It does not require installation, only a licence that is both computer and user specific. The licence is sold by Emmace.

Interested in Mimetikos Preludium™ Software? 

Bo Olsson

Bo Olsson, PhD

Senior Adviser – Inhalation Science

Dr. Olsson has more than 30 years of experience of inhaled formulations having spent about equal time on CMC and clinical pharmacology at his former employer, AstraZeneca. In 2015 he took a position as senior inhalation consultant at Emmace Consulting AB. His specialty is IVIVC with particular emphasis on predicting in vivo outcomes, such as lung disposition, from in vitro data, and is a well-known author and speaker on this topic. For many years he was part of the aerosol committees of USP and EP and member of industry groups such as IPAC-RS and EPAG. He was part of the teams developing the multi-stage liquid impinger, the next generation impactor and the OPC mouth-throat models. He is author and owner of the Mimetikos Preludium software.

Read More About Emmace work